169 related articles for article (PubMed ID: 37574751)
1. Reevaluation of bromodomain ligands targeting BAZ2A.
Cazzanelli G; Vedove AD; Parolin E; D'Agostino VG; Unzue A; Nevado C; Caflisch A; Lolli G
Protein Sci; 2023 Sep; 32(9):e4752. PubMed ID: 37574751
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.
Chen P; Chaikuad A; Bamborough P; Bantscheff M; Bountra C; Chung CW; Fedorov O; Grandi P; Jung D; Lesniak R; Lindon M; Müller S; Philpott M; Prinjha R; Rogers C; Selenski C; Tallant C; Werner T; Willson TM; Knapp S; Drewry DH
J Med Chem; 2016 Feb; 59(4):1410-24. PubMed ID: 25799074
[TBL] [Abstract][Full Text] [Related]
3. Structural Analysis of Small-Molecule Binding to the BAZ2A and BAZ2B Bromodomains.
Dalle Vedove A; Spiliotopoulos D; D'Agostino VG; Marchand JR; Unzue A; Nevado C; Lolli G; Caflisch A
ChemMedChem; 2018 Jul; 13(14):1479-1487. PubMed ID: 29770599
[TBL] [Abstract][Full Text] [Related]
4. Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B.
Drouin L; McGrath S; Vidler LR; Chaikuad A; Monteiro O; Tallant C; Philpott M; Rogers C; Fedorov O; Liu M; Akhtar W; Hayes A; Raynaud F; Müller S; Knapp S; Hoelder S
J Med Chem; 2015 Mar; 58(5):2553-9. PubMed ID: 25719566
[TBL] [Abstract][Full Text] [Related]
5. GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.
Bevill SM; Olivares-Quintero JF; Sciaky N; Golitz BT; Singh D; Beltran AS; Rashid NU; Stuhlmiller TJ; Hale A; Moorman NJ; Santos CM; Angus SP; Zawistowski JS; Johnson GL
Mol Cancer Res; 2019 Jul; 17(7):1503-1518. PubMed ID: 31000582
[TBL] [Abstract][Full Text] [Related]
6. Discovery of BAZ2A bromodomain ligands.
Spiliotopoulos D; Wamhoff EC; Lolli G; Rademacher C; Caflisch A
Eur J Med Chem; 2017 Oct; 139():564-572. PubMed ID: 28837921
[TBL] [Abstract][Full Text] [Related]
7. GSK2801 Reverses Paclitaxel Resistance in Anaplastic Thyroid Cancer Cell Lines through MYCN Downregulation.
Molteni E; Baldan F; Damante G; Allegri L
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983070
[TBL] [Abstract][Full Text] [Related]
8. In vivo CRISPR screening identifies BAZ2 chromatin remodelers as druggable regulators of mammalian liver regeneration.
Jia Y; Li L; Lin YH; Gopal P; Shen S; Zhou K; Yu X; Sharma T; Zhang Y; Siegwart DJ; Ready JM; Zhu H
Cell Stem Cell; 2022 Mar; 29(3):372-385.e8. PubMed ID: 35090595
[TBL] [Abstract][Full Text] [Related]
9. Identification of a BAZ2A Bromodomain Hit Compound by Fragment Joining.
Dalle Vedove A; Cazzanelli G; Corsi J; Sedykh M; D'Agostino VG; Caflisch A; Lolli G
ACS Bio Med Chem Au; 2021 Dec; 1(1):5-10. PubMed ID: 36147311
[TBL] [Abstract][Full Text] [Related]
10. Identification of a BAZ2A-Bromodomain Hit Compound by Fragment Growing.
Dalle Vedove A; Cazzanelli G; Batiste L; Marchand JR; Spiliotopoulos D; Corsi J; D'Agostino VG; Caflisch A; Lolli G
ACS Med Chem Lett; 2022 Sep; 13(9):1434-1443. PubMed ID: 36105334
[TBL] [Abstract][Full Text] [Related]
11. Development of chemical probes for the bromodomains of BRD7 and BRD9.
Clark PG; Dixon DJ; Brennan PE
Drug Discov Today Technol; 2016 Mar; 19():73-80. PubMed ID: 27769361
[TBL] [Abstract][Full Text] [Related]
12. Rational Design and Development of Selective BRD7 Bromodomain Inhibitors and Their Activity in Prostate Cancer.
Ordonez-Rubiano SC; Maschinot CA; Wang S; Sood S; Baracaldo-Lancheros LF; Strohmier BP; McQuade AJ; Smith BC; Dykhuizen EC
J Med Chem; 2023 Aug; 66(16):11250-11270. PubMed ID: 37552884
[TBL] [Abstract][Full Text] [Related]
13. BAZ2A-mediated repression via H3K14ac-marked enhancers promotes prostate cancer stem cells.
Peña-Hernández R; Aprigliano R; Carina Frommel S; Pietrzak K; Steiger S; Roganowicz M; Lerra L; Bizzarro J; Santoro R
EMBO Rep; 2021 Nov; 22(11):e53014. PubMed ID: 34403195
[TBL] [Abstract][Full Text] [Related]
14. Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
Zou LJ; Xiang QP; Xue XQ; Zhang C; Li CC; Wang C; Li Q; Wang R; Wu S; Zhou YL; Zhang Y; Xu Y
Acta Pharmacol Sin; 2019 Nov; 40(11):1436-1447. PubMed ID: 31097763
[TBL] [Abstract][Full Text] [Related]
15. Binding Selectivity of Inhibitors toward Bromodomains BAZ2A and BAZ2B Uncovered by Multiple Short Molecular Dynamics Simulations and MM-GBSA Calculations.
Wang L; Wang Y; Yang Z; Xu S; Li H
ACS Omega; 2021 May; 6(18):12036-12049. PubMed ID: 34056358
[TBL] [Abstract][Full Text] [Related]
16. Biological function and histone recognition of family IV bromodomain-containing proteins.
Lloyd JT; Glass KC
J Cell Physiol; 2018 Mar; 233(3):1877-1886. PubMed ID: 28500727
[TBL] [Abstract][Full Text] [Related]
17. Structural Basis of Inhibitor Selectivity in the BRD7/9 Subfamily of Bromodomains.
Karim RM; Chan A; Zhu JY; Schönbrunn E
J Med Chem; 2020 Mar; 63(6):3227-3237. PubMed ID: 32091206
[TBL] [Abstract][Full Text] [Related]
18. Recognition of hyperacetylated N-terminus of H2AZ by TbBDF2 from
Yang X; Wu X; Zhang J; Zhang X; Xu C; Liao S; Tu X
Biochem J; 2017 Nov; 474(22):3817-3830. PubMed ID: 29025975
[TBL] [Abstract][Full Text] [Related]
19. Selective recognition of acetylated histones by bromodomains in transcriptional co-activators.
Hassan AH; Awad S; Al-Natour Z; Othman S; Mustafa F; Rizvi TA
Biochem J; 2007 Feb; 402(1):125-33. PubMed ID: 17049045
[TBL] [Abstract][Full Text] [Related]
20. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.
Theodoulou NH; Bamborough P; Bannister AJ; Becher I; Bit RA; Che KH; Chung CW; Dittmann A; Drewes G; Drewry DH; Gordon L; Grandi P; Leveridge M; Lindon M; Michon AM; Molnar J; Robson SC; Tomkinson NC; Kouzarides T; Prinjha RK; Humphreys PG
J Med Chem; 2016 Feb; 59(4):1425-39. PubMed ID: 25856009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
